The Sermorelin clinical trial landscape is one of the most misread topics in peptide research. Search ClinicalTrials.gov for “sermorelin” and you get dozens of hits — which looks like an active research program until you open the records and discover that most of them studied a different compound entirely. This guide walks through the Sermorelin clinical trial landscape exactly as the registry shows it: how many studies the search returns, which ones genuinely involve sermorelin, why the rest are there, what the status labels mean, and why the compound’s most important trials predate the registry itself. Factual registry data only — no invented trial numbers, no borrowed prestige.
Research-use-only disclaimer: Sermorelin is not currently an FDA-approved drug and is not a medicine. It is handled as a research compound for laboratory and scientific investigation only. This Sermorelin clinical trial landscape article is an educational overview of public registry data. It contains no dosage information, no usage instructions, and no medical advice.
The Sermorelin Clinical Trial Landscape in Four Numbers
Here is the Sermorelin clinical trial landscape reduced to the four numbers that matter — each one verified against the public registry:
42 studies — the number returned by a ClinicalTrials.gov expert search for “sermorelin” (registry query history, September 2026). That is the headline count, and it is misleading on its own.
Most are not sermorelin. The search is a text match: it returns any record mentioning “growth hormone releasing hormone,” which sweeps in trials of tesamorelin — a different, 44-amino-acid GHRH analog. Opening records is the only way to tell them apart.
1 verified Geref-era study. Among the records examined for this Sermorelin clinical trial landscape guide, NCT03018886 is the clearly documented case of a registered study using genuine Geref-era sermorelin — a diagnostic validation study run in Helsinki.
0 modern therapeutic trials. No verifiable Phase 2 or Phase 3 trial of sermorelin as a therapeutic agent appears in the current registry — consistent with a compound whose approval era ended in 2008.
Selected Registry Entries: The Sermorelin Clinical Trial Landscape Up Close
The table below shows representative entries from the Sermorelin clinical trial landscape search results — the NCT number, the record’s title and condition, its location and status as listed, and what the intervention field actually says. This is the level of detail at which the landscape becomes honest:
| NCT number | Title (as registered) | Condition / location | Status | Intervention (as registered) |
|---|---|---|---|---|
| NCT03018886 | Diagnosing Adult Growth Hormone Deficiency | Growth hormone deficiency; Helsinki, Finland | Completed | GHRH(1-29), GEREF (Serono) — genuine sermorelin |
| NCT00000380 | GHRH Treatment for Age-Related Sleep Disturbances | Sleep disorders; location not provided | Completed | Synthetic GHRH vs placebo — confirm fragment on record |
| NCT00850564 | Effect of Short Term GHRH in Healthy Men | Healthy volunteers; Boston, MA | Completed | Tesamorelin — different compound |
| NCT00795210 | Effects of Short-term Growth Hormone in HIV-infected Patients | HIV lipodystrophy; Boston, MA | Completed | Tesamorelin — different compound |
| NCT01263717 | (HIV lipodystrophy study) | HIV / HIV lipodystrophy; Boston, MA | Completed | GHRH-analog program — check record before citing |
| NCT03375788 | (Fatty liver / obesity study) | NAFLD, obesity; Boston, MA | Completed | GHRH-analog program — check record before citing |
| NCT01410799 | (Aging / hormone deficiency study) | Aging, hormone deficiency; Philadelphia, PA | Terminated | Check intervention field on the record |
| NCT00807365 | (Elderly study) | Elderly; Baltimore, MD / Boston, MA | Terminated | Check intervention field on the record |
| NCT01632592 | (Abdominal obesity study) | Abdominal obesity; Boston, MA | Withdrawn | Check intervention field on the record |
The pattern in the Sermorelin clinical trial landscape is visible in the last column: the Boston-centered cluster of metabolic studies belongs to the tesamorelin research program, while the genuine sermorelin entries are the diagnostic studies. A researcher who cites from the search-results page without opening records will systematically misattribute the larger program to the smaller compound.
Why 42 Studies Is Not 42 Sermorelin Studies
The central mechanic of the Sermorelin clinical trial landscape is how ClinicalTrials.gov search works: it matches text across record fields, not chemical identity. “Sermorelin” as a search term matches records containing “growth hormone releasing hormone” — the phrase that describes the entire drug class. Tesamorelin trials, which test a different molecule, contain that phrase and therefore appear. The registry is doing its job correctly; the misreading happens when a count of search hits is reported as a count of sermorelin trials.
This is not a sermorelin-specific quirk. Any compound whose name overlaps with its class description produces the same effect in the Sermorelin clinical trial landscape and beyond. The professional habit is always the same: the search result is a lead list, and the intervention field on each record is the verdict. NCT00850564 demonstrates the payoff — its title says “Growth Hormone Releasing Hormone,” but its intervention field says tesamorelin, settling the question in one line.
Search hits ≠ trials of the compound. In the Sermorelin clinical trial landscape, the majority of the 42 search results belong to the tesamorelin program. Any article, vendor page, or video that cites the raw hit count as evidence of sermorelin research activity has skipped the only step that matters: opening the records.
The Genuine Sermorelin Entries
Within the Sermorelin clinical trial landscape, the entries that clearly involve sermorelin itself are the diagnostic-era studies. NCT03018886 (“Diagnosing Adult Growth Hormone Deficiency”) is the exemplar: run in Helsinki, it validated the GHRH-plus-arginine stimulation test and its cut-offs for adult growth hormone deficiency in 160 participants (126 healthy controls and 34 patients with suspected deficiency), with the registry record explicitly naming GHRH(1-29), GEREF, Serono, Italy as the test agent. The study ran from 2001 to 2008, was registered in 2017, and is listed as completed with a diagnostic (not therapeutic) purpose.
NCT00000380 (“GHRH Treatment for Age-Related Sleep Disturbances”) sits at the boundary: a completed registered study of synthetic GHRH versus placebo in 80 older adults, measuring sleep quality, 24-hour GH secretion patterns, and IGF-1 — with a linked 2006 publication on GHRH and cognition in healthy older adults. The record describes the intervention as synthetic GHRH, so a careful reader of the Sermorelin clinical trial landscape confirms the exact fragment in the study documents before filing it under sermorelin specifically. That “confirm, don’t assume” posture is the whole discipline in miniature.
Reading Registry Status Labels Correctly
Status labels in the Sermorelin clinical trial landscape carry precise meanings that writers routinely blur. A quick decoder for the labels appearing in the table above:
| Status | What it means | What it does not mean |
|---|---|---|
| Completed | The study ran its course per protocol | Does not imply positive results — or any published results |
| Terminated | Stopped early, before completion | Does not by itself explain why; reasons vary |
| Withdrawn | Halted before enrolling anyone | Not a finding about the compound at all |
| Recruiting / Active | Currently enrolling or in follow-up | None of the sermorelin-search entries currently show this |
Two entries in the Sermorelin clinical trial landscape — NCT01410799 and NCT00807365 — carry “Terminated” status, and one — NCT01632592 — is “Withdrawn.” Those labels describe trial conduct, not compound efficacy, and none of the three should be cited as evidence about sermorelin’s properties. Equally, “Completed” on NCT03018886 or NCT00850564 means the protocol finished — results may or may not be posted, and the results tab on each record is where that question gets answered. Researchers can verify any of this directly at ClinicalTrials.gov.
Why the Approval-Era Trials Are Not in the Registry
A newcomer to the Sermorelin clinical trial landscape might ask the obvious question: if sermorelin was FDA-approved in 1997, where are the pivotal trials? The answer is chronological. ClinicalTrials.gov launched in 2000; the results-reporting requirements that made registration comprehensive arrived with later legislation. The Geref development program — the clinical work behind the 1997 approval for pediatric growth hormone deficiency and diagnostic use — simply predates the registry era. Its record lives in the FDA approval package and the contemporary literature, not in NCT-numbered entries.
This creates the defining asymmetry of the Sermorelin clinical trial landscape: the compound’s most important clinical program is invisible to registry-only research, while the registry-visible program is dominated by a different compound’s trials. Both halves of that asymmetry are factual, and both must be stated together — the registry tells you what has been registered, not what has been studied. The FDA’s drug information pages remain the canonical source for the approval-history half of the story.
The registry is a record of registrations. That sentence is the key to the entire Sermorelin clinical trial landscape: absence from ClinicalTrials.gov means absence from the registry, not absence from history. Sermorelin’s approval-era trials happened before registration was the norm — which is precisely why registry-only summaries of this compound go wrong.
How to Verify Any Sermorelin Trial Claim in Five Minutes
The practical payoff of this Sermorelin clinical trial landscape guide is a verification routine any researcher can run. Use it on every trial claim you encounter:
- ☐ Search ClinicalTrials.gov for the compound and note the raw hit count — then treat it as a lead list, not a finding.
- ☐ Open each candidate record and read the intervention field: does it name sermorelin, or a neighboring GHRH analog like tesamorelin?
- ☐ Check the status label (completed, terminated, withdrawn) and read it with the decoder table above — not as a result.
- ☐ Check the results tab and the linked publications: is there posted data, a PubMed-indexed paper, or neither?
- ☐ For pre-2000 claims, look beyond the registry: FDA approval packages and contemporary literature are where approval-era trials live.
- ☐ Cite the NCT number and the intervention exactly as registered — never the search-result snippet.
That routine is also the standard this site applies to its own research content. Our Selank vs Semax research comparison names exact compounds and primary sources throughout, and our Semax nasal spray and Selank nasal spray overviews keep the same registry discipline. For indexed literature behind any trial claim, PubMed is the shared reference desk.
Key Takeaways: Sermorelin Clinical Trial Landscape
A “sermorelin” registry search returns 42 studies, but most are tesamorelin trials caught by text matching — the genuine sermorelin entries are diagnostic-era studies like NCT03018886. No modern Phase 2/3 therapeutic trial of sermorelin is registered, and the pivotal approval-era trials predate the registry itself. Verify via the intervention field, read status labels precisely, and cite NCT numbers exactly as registered. (Research framing only — registry data, not research or usage advice.)
Sermorelin Clinical Trial Landscape: Final Research Notes
The honest Sermorelin clinical trial landscape is smaller and more instructive than the search-hit count suggests: a pre-registry approval program, a handful of registered diagnostic studies using genuine Geref-era material, a boundary literature on GHRH and sleep/cognition, and a large neighboring tesamorelin program that text search keeps sweeping into the frame. The landscape rewards one skill above all — opening the record and reading the intervention field — and punishes the shortcut of citing counts instead of studies.
For researchers who want the study-by-study version of this story, our companion guide covers the Sermorelin clinical trial landscape from the literature side as well. And for laboratory reference materials handled with the same documentation discipline described here, see our Semax 10mg and Selank 10mg research listings. The registry is public, the records are checkable, and now you know how to read them.
Sermorelin Clinical Trial Landscape: Frequently Asked Questions
Quick answers to the questions researchers ask most about the registry record.
How many sermorelin trials are registered on ClinicalTrials.gov?
A text search for “sermorelin” returns 42 studies, but most are tesamorelin trials caught by text matching — not sermorelin trials. In the Sermorelin clinical trial landscape, the honestly countable registered studies of sermorelin itself are the diagnostic-era entries, led by NCT03018886. The hit count is a lead list, not a finding.
What is NCT03018886?
“Diagnosing Adult Growth Hormone Deficiency” — a completed, registered study run in Helsinki that validated the GHRH-plus-arginine stimulation test in 160 participants, using GHRH(1-29), GEREF (Serono) — genuine sermorelin — as the test agent. It is the clearest entry in the Sermorelin clinical trial landscape.
Why do tesamorelin trials appear in sermorelin searches?
ClinicalTrials.gov matches search text across record fields, and tesamorelin records contain the phrase “growth hormone releasing hormone.” Tesamorelin is a different, 44-amino-acid GHRH analog. The registry rule: always check the intervention field on the record itself.
Are there any ongoing sermorelin trials?
No currently recruiting or active interventional trial of sermorelin appears in the registry entries reviewed for this registry guide. The visible entries are completed, terminated, or withdrawn — and the terminated/withdrawn labels describe trial conduct, not compound findings.
Where are sermorelin’s original approval trials?
They predate the registry: Geref was FDA-approved in 1997, ClinicalTrials.gov launched in 2000, and comprehensive results reporting came later. The pivotal trials live in the FDA approval package and contemporary literature — a defining feature of the Sermorelin clinical trial landscape.
How do I verify a sermorelin trial claim myself?
Search ClinicalTrials.gov, open the record, confirm the intervention field names sermorelin (not a neighboring analog), read the status label precisely, check the results tab and linked publications, and cite the NCT number exactly as registered. That five-minute routine is the practical core of this Sermorelin clinical trial landscape guide.
